| Literature DB >> 35744824 |
Alaa Z Omar1, Najla A Alshaye2, Tawfik M Mosa1, Samir K El-Sadany1, Ezzat A Hamed1, Mohamed A El-Atawy1,3.
Abstract
A new N,N'-disubstituted piperazine conjugated with 1,3,4-thiadiazole and 1,2,4-triazole was prepared and the chemical structures were identified by IR, NMR and elemental analysis. All the prepared compounds were tested for their antimicrobial activity. The antimicrobial results indicated that the tested compounds showed significant antibacterial activity against gram-negative strains, especially E. coli, relative to gram-positive bacteria. Docking analysis was performed to support the biological results; binding modes with the active site of enoyl reductase amino acids from E. coli showed very good scores, ranging from -6.1090 to -9.6184 kcal/mol. Correlation analysis was performed for the inhibition zone (nm) and the docking score.Entities:
Keywords: 1,2,4-triazole; 1,3,4-thiadiazole; MOE; enoyl reductase; piperazine
Mesh:
Substances:
Year: 2022 PMID: 35744824 PMCID: PMC9228617 DOI: 10.3390/molecules27123698
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Example of market drugs containing thiadiazole and piperazine moieties.
Scheme 1Functionalization of 5,5′-(piperazin-1,4-diyl)bis(1,3,4-thiadiazole-2-thiol).
Scheme 2Synthesis of piperazine containing 1,4-bis(1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole) moiety.
Scheme 3Reaction of 1,4-bis(5-chloro-1,3,4-thiadiazol-2-yl)piperazine 3 with sulfur and nitrogen nucleophiles.
Antimicrobial activities of piperazines 2–10.
| Compounds | Antibacterial Activity | Antifungal Activity | ||||
|---|---|---|---|---|---|---|
| G+ Bacteria | G− Bacteria | |||||
|
|
|
|
|
|
| |
|
| 26 | 24 | 27 | 16 | 18 | 11 |
|
| 21 | 22 | 30 | 27 | 18 | 15 |
|
| 38 | 25 | 29 | 15 | 18 | 16 |
|
| 19 | 18 | 31 | 15 | 19 | 14 |
|
| 22 | 24 | 34 | 23 | 17 | 11 |
|
| 21 | 25 | 35 | 19 | 15 | 17 |
|
| 30 | 23 | 36 | 24 | 13 | 12 |
|
| 32 | 39 | 35 | 10 | 8 | 10 |
|
| 23 | 19 | 36 | 24 | 11 | 10 |
|
| 22 | 32 | 35 | 20 | 11 | 11 |
|
| 15 | 13 | 33 | 22 | 10 | 15 |
|
| 23 | 10 | 31 | 11 | 10 | 6 |
|
| 20 | 11 | 31 | 19 | 11 | 7 |
| Ketoconazole | - | - | - | - | 20 | 16 |
| Gentamycin | 24 | 26 | 30 | 30 | - | - |
The minimal inhibitory concentration (MIC: μg/mL) of compounds 2–10.
| Compounds |
|
|
|
|
|---|---|---|---|---|
|
| 32 | 32 | 64 | 256 |
|
| 64 | 32 | 16 | 32 |
|
| 16 | 32 | 32 | 256 |
|
| 64 | 256 | 32 | 256 |
|
| 32 | 32 | 16 | 64 |
|
| 64 | 32 | 16 | 256 |
|
| 16 | 64 | 8 | 64 |
|
| 16 | 16 | 16 | 256 |
|
| 32 | 64 | 16 | 64 |
|
| 32 | 16 | 16 | 64 |
|
| 265 | 256 | 16 | 64 |
|
| 32 | 256 | 32 | 256 |
|
| 63 | 256 | 32 | 256 |
| Gentamycin | 32 | 32 | 16 | 16 |
Docking results of 2–10 docked into enoyl reductase.
| Ligand | S | Distance (Å) between TYR 158 and Ligand | Type of Interaction | Distance (Å) | Energy of Each Interaction |
|---|---|---|---|---|---|
|
| −6.0611 | 3.89 | H-donor (ALA 191) | 3.56 | −1.0 |
| H-donor (GLY 96) | 3.73 | −0.6 | |||
|
| −6.7247 | – | H-donor (THR 196) | 3.18 | −0.6 |
| H-acceptor (VAL 65) | 3.25 | 7.1 | |||
|
| −6.1899 | 3.93 | H-donor (GLY 96) | 3.42 | −0.6 |
|
| −6.6629 | 2.27 | H-donor (GLY 192) | 3.34 | −0.7 |
| H-acceptor (LYS 165) | 3.36 | 1.1 | |||
| pi-pi (PHE 149) | 3.65 | −0.1 | |||
|
| −6.0934 | 2.65 | H-donor (MET 103) | 3.96 | −1.5 |
| H-donor (PHE 41) | 3.30 | −1.7 | |||
| H-acceptor (PHE 41) | 3.36 | −0.9 | |||
| pi-H (ILE 16) | 3.71 | −0.6 | |||
| pi-H (MET 161) | 3.77 | −1.0 | |||
| pi-H (MET 161) | 4.25 | −0.7 | |||
|
| −8.3435 | 2.75 | H-donor (ILE 194) | 3.41 | −0.8 |
| H-donor (ILE 194) | 3.88 | −0.7 | |||
| H-acceptor (GLY 96) | 3.21 | −3.4 | |||
| pi-pi (PHE 149) | 3.90 | −0.1 | |||
|
| −9.9114 | 2.69 | H-donor (MET 199) | 3.81 | −0.7 |
| H-acceptor (GLY 96) | 3.40 | −2.1 | |||
| H-acceptor (GLY 14) | 3.26 | −0.8 | |||
| pi-pi (PHE 149) | 3.78 | −0.1 | |||
|
| −9.3629 | 2.07 | H-donor (THR 39) | 3.64 | −1.0 |
| H-donor (ALA 191) | 4.01 | −0.4 | |||
| H-donor (SER 94) | 4.07 | −1.4 | |||
| pi-pi (PHE 149) | 3.96 | −0.1 | |||
|
| −9.1279 | 2.67 | H-acceptor (GLY 96) | 3.07 | −3.1 |
| H-acceptor (ILE 194) | 3.47 | −1.0 | |||
|
| −9.3123 | 3.26 | H-donor (TYR 158) | 3.35 | −0.8 |
| H-acceptor (VAL 65) | 3.03 | −2.9 | |||
|
| −8.8790 | 2.72 | H-donor (ASP 64) | 2.73 | −6.4 |
| H-donor (TYR 158) | 3.63 | −1.2 | |||
| pi-H (GLY 96) | 4.38 | −2.3 | |||
| pi-H (PHE 149) | 3.89 | −1.0 | |||
|
| −7.4755 | 2.19 | H-donor (GLY 14) | 3.26 | −0.1 |
| H-donor (PHE 41) | 3.90 | −1.2 | |||
|
| −8.3385 | 2.60 | H-donor (GLY 96) | 3.39 | −0.9 |
| pi-pi (PHE 41) | 3.51 | −0.1 | |||
|
| −7.7983 | 2.60 | H-acceptor (LYS 165) | 3.25 | 3.2 |
| pi-H (GLY 96) | 4.11 | −0.6 | |||
| TCL | −5.8149 | 2.78 | H-donor (GLY 96) | 3.04 | −2.5 |
Figure 2Design strategy of novel piperazines bearing thiadiazole moiety as antimicrobial drugs.
Figure 32D (left) and 3D (right) binding modes of selected compounds (green tube) in enoyl reductase active sites (PDB: 1C14 [68]).